trending Market Intelligence /marketintelligence/en/news-insights/trending/fObG2a2NjZ64AVrUd1RDCA2 content esgSubNav
In This List

Erytech Pharma refiles application for blood cancer drug in Europe

Blog

Post-webinar Q&A: Global Credit Risk Trends 2021 and Beyond

Blog

University Essentials: From Crisis to Resilience – Navigating Sustainable Recovery

Blog

EV impact; vaccines to boost job market; coal supply constraints

Blog

Shore Capital is Now Available in S&P Global’s Aftermarket Research Collection


Erytech Pharma refiles application for blood cancer drug in Europe

Erytech Pharma SA resubmitted its application for Graspa with the European Medicine Agency to treat a type of blood cancer.

Graspa, also known as eryaspase, will be used to treat relapsed or refractory acute lymphoblastic leukemia, or ALL, a blood cancer affecting mainly the white blood cells.

The resubmission includes data from a phase 2/3 study in children and adults with ALL, along with additional data to address questions from the EMA's Committee for Medicinal Products for Human Use.

The clinical data showed that Graspa, in combination with chemotherapy, was more safe and effective than native L-asparaginase.

Erytech had withdrawn its original regulatory application in November 2016 to address the EMA's request for additional data.

The American Cancer Society estimates that about 5,970 new cases of ALL will be diagnosed in the U.S. in 2017, resulting in roughly 1,440 deaths. Erytech estimates that Europe records about the same number of ALL cases annually.